Abstract
Purpose
Proteomic studies suggest an association between haptoglobin (Hp) and polycystic ovary syndrome (PCOS). Hp is a classic inflammatory marker and binds to the intravascular hemoglobin, avoiding the oxidative damages that can be caused by free hemoglobin. Inflammation and oxidative stress are important in the pathogenesis of the PCOS, one of the most frequent metabolic diseases in women.
Methods
To validate these proteomic studies, we developed a controlled cross-sectional study that aimed to evaluate the Hp levels and allelic and genotypic frequencies of Hp1-Hp2 polymorphism in Brazilian women with PCOS. We also investigated the correlation between Hp levels and several important parameters in PCOS as follows: body mass index (BMI), waist circumference (WC), fasting glucose, post-prandial glucose, homeostatic model assessment (HOMA), lipid accumulation product (LAP), C-reactive protein (CRP), and metabolization test of tetrazolium salts (MTTs—serum antioxidant capacity).
Results
Plasma Hp levels were higher in the PCOS group than in controls [8.20 (4.04) g/L; 7.98 (3.31) g/L; p = 0.018]. No significant difference was observed in the frequency of Hp1-Hp2 genotypes under additive, recessive, or dominant model of inheritance between the PCOS and the control groups. Plasma Hp levels did not differ according to the genotype. However, plasma Hp showed a negative correlation with MTT (r = − 0.383; p = 0.028), as well as a positive correlation with CRP (r = 0.361; p = 0.014) in the PCOS group.
Conclusion
Hp1-Hp2 polymorphism is not associated with PCOS but plasma Hp could be a potential biomarker for PCOS and its complications.
Similar content being viewed by others
References
Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol. 2017. https://doi.org/10.23736/S0391-1977.17.02609-8.
Palomba S, Falbo SSA, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;7:745–63.
Silva FS, Sóter MO, Sales MF, Candido AL, Reis FM, Silva IF, et al. Estrogen receptor alpha gene (ESR1) Pvu II and Xba I polymorphisms are associated to metabolic and proinflammatory factors in polycystic ovary syndrome. Gene. 2015;560:44–9.
Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodaee Z, Akbari M. Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: a meta-analysis. Iran J Reprod Med. 2015;13(10):591–604.
Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13.
Gonzalez F, Kirwanj P, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl Thromb Hemost. 2013;19(1):66–72.
Shen CC, Yang AC, Hung J, Hu LY, Tsai J. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist. 2015;20(1):45–9.
Yu HF, Chen HS, Rao DP, Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(51):48–63.
Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149(5):R219–27.
Sóter MO, Ferreira CN, Sales MF, Candido AL, Reis FM, Milagres KS, et al. Peripheral blood-derived cytokine gene polymorphisms and metabolic profile in women with polycystic ovary syndrome. Cytokine. 2015;76(2):227–35.
Aytan AN, Bastu E, Demiral I, Blulut H, Dogan M, Buyry F. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol. 2016;19(24):1–5.
Carvalho LM, Ferreira CN, Sóter MO, Sales MF, Rodrigues KF, Martins SR, et al. Microparticles: inflammatory and haemostatic biomarkers in polycystic ovary syndrome. Mol Cell Endocrinol. 2017;443:155–62.
Mortada R, Kallail KJ, Dong F, Karakas S. HbA1c in patients with polycystic ovary syndrome: a potential marker of inflammation. J Reprod Infertil. 2015;16(4):203–6.
Özer A, Bakacak M, Kıran H, Ercan Ö, Köstü B, Kanat-Pektaş M, et al. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome. Ginekol Pol. 2016;87(11):733–8.
Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013;19(3):268–88.
Insenser M, Martínez-García MA, Montes R, San-Millán JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab. 2010;95(8):3863–70.
Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, Creaser C, et al. Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. J Proteome Res. 2007;6:3321–8.
Ashleh R, Marsh S, Skilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Mol Med. 2003;92:1193–200.
Costacou T, Levy AP. Haptoglobin genotype and its role in diabetic cardiovascular disease. J Cardiovasc Transl Res. 2012;5(4):423–35.
Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SKA, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201.
Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589–600.
Shaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res. 2006;99(9):943–50.
Berkova N, Gilbert C, Goupil S, Yan J, Korobko V, Naccache PH. TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 receptor. J Immunol. 1999;162:6226–32.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–54.
Nakata K, Saitoh R, Aamano J, Koshiyama A, Ichibangase T, Murao N, et al. Alteration of intracellular secretory acute phase response proteins expressed in human hepatocyte induced by exposure with interleukin-6. Cytokine. 2012;59(2):317–23.
Baumann H, Morella KK, Jahreis GP, Marinković S. Distinct regulation of the interleukin-1 and interleukin-6 response elements of the rat haptoglobin gene in rat and human hepatoma cells. Mol Cell Biol. 1990;10(11):5967–76.
Friedrichs WE, Navarijo-Ashbaugh AL, Bowman BH, Yang F. Expression and inflammatory regulation of haptoglobin gene in adipocytes. Biochem Biophys Res Commun. 1995;209(1):250–6.
Kalmovarin N, Friedrichs WE, O’Brien OV, Linehan LA, Bowman BH, Yang F. Extrahepatic expression of plasma protein genes during inflammation. Inflammation. 1991;15(5):369–79.
Chiellini C, Santini F, Marsili A, Berti P, Bertacca A, Pelosini C, et al. Serum haptoglobin: a novel marker of adiposity in humans. Journal of Endocrinology and Metabolism. 2004;89(6):2678–83.
Maffei M, Barone I, Scabia G, Santini F. The multifaceted haptoglobin in the context of adipose tissue and metabolism. Endocr Rev. 2016;37(4):403–16.
Farbstein D, Levy AP. The genetics of vascular complications in diabetes mellitus. Cardiol Clin. 2010;28(3):477–96.
Szafranek T, Marsh S, Levy AP. Haptoglobin: a major susceptibility gene for diabetic vascular complications. Exp Clin Cardiol. 2002;7(2/3):113–9.
Gast MCW, Tinteren HV, Bontenban M, Van Hoesel RGCM, Nooji MA, Rodenhuis S, et al. Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer. 2008;8:389.
Orchard TJ, Sun W, Cleary PA, Genuth SM, Lachin JM, Mcgee P, et al. Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes. 2013;62(9):3218–23.
Boettger LM, Salem RM, Handsaker RE, Peloso GM, Kathiresan S, Hirschhorn JN, et al. Recurring exon deletions in the HP (haptoglobin) gene contribute to lower blood cholesterol levels. Nat Genet. 2016;48(4):359–66.
Alvarez-Blasco F, Martínez-García MA, Luque-Ramírez M, Parraza N, San Millán JL, Escobar-Morreale HF. Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women. PLoS One. 2009;4(5):e5606.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.
Api M, Badoglu B, Akca A, Api O, Gorden H, Cetin A. Interobserver variability of modiWedFerriman–Gallwey hirsutism score in a Turkish population. Arch Gynecol Obstet. 2009;279:473–9.
Wen-Ya M, Chung-Yi Y, Shyang-Rong S, Hong-Jen H, Chi SH, Fu-Chun C, et al. Measurement of waist circumference: midabdominal or iliac crest? Diabetes Care. 2013;36:1660–6.
Lwow F, Jedrzejuk D, Milewicz A, Szmigiero L. Lipid accumulation product (LAP) as a criterion for the identification of the healthy obesity phenotype in postmenopausal women. Exp Gerontol. 2016;82:81–7.
Godinjak A, Godinjak Z, Burekovic A, Surkovic I, Dizdarecic-Bostandizic A, Velija-asimi Z. Insulin resistance and lipid accumulation product in correlation to body mass index in women with polycystic ovary syndrome. Med Arch. 2012;66:409–11.
Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: developments in research and prospects for the future. Drug Discov Ther. 2015;9:380–5.
Liu Y, Nair MG. Efficient and economical MTT assay for determining the antioxidant activity of plant natural product extracts and pure compounds. J Nat Prod. 2010;73(7):1193–5.
Duarte RCF, Golçalves LH, Campos FMF, Filho OAM, Alves MT, Fernandes AP, et al. Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus. Blood Coagul Fibrinolysis. 2014;25:01–8.
Medina LO, Veloso CA, Abreu Borges E, Isoni CA, Calsolari MR, Nogueira-Machado JÁ. Determination of the antioxidant status of plasma from type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77:193–7.
Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schömig A, et al. Genotyping of the common haptoglobin Hp1/2 polymorphism based on PCR. Clin Chem. 2002;48(9):1377–82.
Taylor R. Interpretation of the correlation coefficient: a basic review. J Diagn Med Sonography. 1990;6:35–9.
GENEPOP. http://genepop.curtin.edu.au/genepop_op1.html. Accessed 5 Mar 2017.
OEGE. http://www.oege.org/software/hardy-weinberg.html. Accessed 5 Mar 2017.
Bachelot A. Polycystic ovarian syndrome: clinical and biological diagnosis. Ann Biol Clin. 2016;74(6):661–7.
Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol. 2016;32(3):177–83.
Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56(3):137–42.
Kushner MAI. It’s time to redefine inflammation. J Clin Endocrinol Metab. 2010;95(8):3863–70.
Haoula Z, Shaw B, Daykin C, Hodgman C, Layfield R, Atiomo W. Validation of proteomic biomarkers previously found to be differentially expressed in women with polycystic ovary syndrome: a cross-sectional study. Gynecol Endocrinol. 2014;30(3):213–6.
Chiellini C, Bertacca A, Novelli SE, et al. Obesity modulates the expression of haptoglobin in the white adipose tissue via TNF-α. J Cell Physiol. 2002;190(2):251–8.
De Pergola G, Di Roma P, Paoli G, Guida P, Pannacciulli N, et al. Haptoglobin serum levels are independently associated with insulinemia in overweight and obese women. J Endocrinol Investig. 2007;30:399–403.
Acknowledgements
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) for the financial support. FMR and KBG are grateful to CNPq Research Fellowship. Simone Martins Gonçalves, Dalva Maria de Resende, for technical support. Special thanks to the patients involved in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was approved by the ethics committees of Federal University of Minas Gerais (Minas Gerais, Brazil)—CAAE 0379.0.203.000-11. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All the women who participated in this study signed a free and informed consent form.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Carvalho, L.M.L., Ferreira, C.N., de Oliveira, D.K.D. et al. Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome. J Assist Reprod Genet 34, 1691–1698 (2017). https://doi.org/10.1007/s10815-017-1030-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-017-1030-3